medical supervision for glp-1 medications Risks Without Guidance The Role of GLP-1RA Medications
Description
In the absence of disease-modifying treatments, the US Food and Drug Administration (FDA) has characterized OA as a serious disease [3]
SOURCE Alzheimer's Association
However, a clinical study from 2022 reported that hair loss (alopecia) occurred in 4.9% to 5.7% of people using a 5 mg to 15 mg dose of Mounjaro, compared to 0.9% of those using the placebo
While research is ongoing, these findings indicate that GLP-1 medications may support airway health directlyoffering a new dimension to sleep apnea treatment
